Investors Sell Allergan PLC (AGN) on Strength (AGN)
Traders sold shares of Allergan PLC (NYSE:AGN) on strength during trading on Friday. $123.68 million flowed into the stock on the tick-up and $141.79 million flowed out of the stock on the tick-down, for a money net flow of $18.11 million out of the stock. Of all equities tracked, Allergan PLC had the 0th highest net out-flow for the day. Allergan PLC traded up $3.22 for the day and closed at $237.76
AGN has been the topic of several recent research reports. Piper Jaffray Cos. reiterated a “cautious” rating and set a $236.00 price objective (down previously from $238.00) on shares of Allergan PLC in a research report on Wednesday, May 11th. Mizuho upgraded Allergan PLC from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $248.00 to $318.00 in a research report on Friday, August 19th. Vetr upgraded Allergan PLC from a “buy” rating to a “strong-buy” rating and set a $288.87 price objective on the stock in a research report on Monday, August 22nd. Citigroup Inc. reiterated a “buy” rating and set a $285.00 price objective on shares of Allergan PLC in a research report on Wednesday, May 11th. Finally, Wells Fargo & Co. restated a “buy” rating on shares of Allergan PLC in a research report on Friday, June 10th. Six investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $309.13.
The firm has a 50 day moving average price of $248.09 and a 200 day moving average price of $247.61. The firm has a market capitalization of $93.43 billion and a price-to-earnings ratio of 22.47.
Allergan PLC (NYSE:AGN) last announced its earnings results on Monday, August 8th. The company reported $3.35 earnings per share for the quarter, topping analysts’ consensus estimates of $3.34 by $0.01. During the same quarter in the prior year, the company earned $4.41 earnings per share. The business earned $3.68 billion during the quarter, compared to the consensus estimate of $4.10 billion. Allergan PLC’s revenue was up 1.0% compared to the same quarter last year. Analysts anticipate that Allergan PLC will post $14.01 EPS for the current year.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.